pyrroles has been researched along with Chronic Disease in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (9.28) | 18.7374 |
| 1990's | 1 (1.03) | 18.2507 |
| 2000's | 36 (37.11) | 29.6817 |
| 2010's | 48 (49.48) | 24.3611 |
| 2020's | 3 (3.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y; Huang, W; Kong, H; Liu, P; Peng, L; Tan, Q; Wang, H; Wang, J; Wang, Y; Xie, W; Yang, M; Yu, M; Zhou, H | 1 |
| Jin, R; Jin, Z; Paudel, O; Sham, JSK; Xia, L; Xia, Y | 1 |
| Arca, KN; Chiang, CC; Dodick, DW; Dunn, RB; Girardo, ME; Quillen, JK; Starling, AJ | 1 |
| Fukahori, H; Hanaoka, K; Hirose, J; Inami, M; Ito, M; Kaneko, Y; Kawato, Y; Kubo, K; Maeda, M; Morokata, T; Nakamura, K; Nakanishi, T; Noto, T | 1 |
| Ishimura, N; Kinoshita, Y | 1 |
| Arbeit, R; Kanhoush, R; Noell, C | 1 |
| Banon-Maneus, E; Brunet, M; Campistol, JM; Cucchiari, D; Diekmann, F; Hierro-Garcia, N; Lazo-Rodríguez, M; Moya-Rull, D; Oppenheimer, F; Piñeiro, GJ; Ramírez-Bajo, MJ; Revuelta, I; Rovira, J; Tubita, V; Ventura-Aguiar, P | 1 |
| Chen, D; Chen, G; Gao, P; Jia, D; Jing, ZC; Liu, G; Liu, J; Liu, Q; Lu, A; Qin, Z; Ruan, C; Shen, Y; Tang, J; Wang, XJ; Wang, Y; Ye, J; Yu, Y; Yuan, P; Zhang, J; Zhang, P; Zhou, Y; Zhu, Q; Zuo, C; Zuo, S | 1 |
| Bachelez, H; Chouela, E; Frajzyngier, V; Gottlieb, AB; Gupta, P; Imafuku, S; Kaur, M; Puig, L; Strober, BE; Tan, H; Thaçi, D; Valdez, H; van de Kerkhof, PCM; Wolk, R | 1 |
| Thibault, PK | 1 |
| Chen, Z; Tian, F; Xu, T | 1 |
| Damarla, M; Damico, RL; Hassoun, PM; Johnston, L; Kolb, TM; Peloquin, GL | 1 |
| Cui, W; Hu, HJ; Liu, DM; Liu, J; Wang, Q; Zhang, HL; Zhang, YN | 1 |
| Cai, S; Fu, Z; Hu, J; Huang, C; Liedtke, W; Paudel, O; Sham, JS; Xia, Y | 1 |
| Buonanno, M; Clark, JD; Harness, J; Kawabata, T; Langley, RG; Menter, A; Papp, K; Strober, B; Tan, H; Valdez, H; Wolk, R | 1 |
| Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR | 1 |
| Ciuclan, L; Dong, L; Dubois, G; Duggan, N; Edwards, M; England, K; Hussey, M; Jarai, G; Morrell, NW; Sheppard, K; Simmons, J; Sutton, D; Thomas, M; Van Heeke, G | 1 |
| Chesler, NC; Eickhoff, JC; Golob, M; Lakes, RS; Wang, Z | 1 |
| Albrecht, C; Ansari, AA; Brameier, M; Byrareddy, SN; Dunbar, P; Khowawisetsut, L; Little, DM; Mayne, AE; Pattanapanyasat, K; Russo, R; Takahashi, Y; Villinger, F; Villinger, T; Walter, L | 1 |
| So, A; Varisco, PA | 1 |
| Chang, CH; Chang, YC; Chuang, LM; Lee, YC; Lin, JW; Liu, YC | 1 |
| Couturier, BS; Decaux, G; Gankam Kengne, F; Soupart, A | 1 |
| Carmona, L; Gómez-Reino, JJ; Maneiro, JR; Mera, A; Salgado, E; Souto, A | 1 |
| Bachinsky, M; Bissonnette, R; Foley, P; Griffiths, CE; Gupta, P; Iversen, L; Mallbris, L; Proulx, J; Romiti, R; Rottinghaus, ST; Sofen, H; Tan, H; Valdez, H; Wolk, R | 1 |
| Deng, GH; Deng, YT; He, SS; Jiang, Y; Liu, J; Luo, XM; Mao, YY; Peng, XC; Wang, Y; Wei, YQ; Xia, XY; Zhang, J | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Bachelez, H; Chimenti, S; Gupta, P; Kubanov, A; Lee, JH; Papacharalambous, J; Proulx, J; Strohal, R; Tan, H; Tawadrous, M; Valdez, H; Valenzuela, F; van de Kerkhof, PC; Wolk, R; Yakusevich, V | 1 |
| Abe, M; Buonanno, M; Elewski, B; Feldman, SR; Gottlieb, AB; Gupta, P; Lan, S; Langley, R; Luger, T; Menter, MA; Papp, KA; Proulx, J; Thaci, D; Wolk, R | 1 |
| Koskinen, PK; Palin, N; Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E | 1 |
| Bardazzi, F; Di Lernia, V | 1 |
| Feldman, SR; Gardner, A; Gupta, P; Krueger, JG; Langley, RG; Luo, Y; Mallbris, L; Mebus, C; Papp, KA; Tan, H; Tatulych, S; Thaci, D; Torii, H; Tyring, S; Wolk, R | 1 |
| Mallbris, L; Mamolo, C; Papacharalambous, J; Paul, C; Tan, H; Valdez, H; Valenzuela, F | 1 |
| Bachinsky, M; Griffiths, CE; Kircik, L; Mallbris, L; Mamolo, C; Rottinghaus, ST; Sofen, H; Tan, H; Vender, R | 1 |
| Brown, MB; Goodwill, AG; Kline, JA; McCarthy, BP; Neto-Neves, EM; Persohn, SA; Rezania, S; Territo, PR; Zaretskaia, MV | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Laczi, F | 1 |
| Chaudhuri, R; Donnelly, I; Hothersall, EJ; Lafferty, J; McInnes, I; McMahon, AD; McSharry, C; Meiklejohn, J; Sattar, N; Thomson, NC; Weir, CJ; Wood, S | 1 |
| Campistol Plana, JM | 1 |
| Cui, W; Liu, F; Lu, JC; Pei, WN; Xie, RQ; Yang, C | 1 |
| Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS | 1 |
| Dahlof, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Anker, SD; Földes, G; von Haehling, S | 1 |
| Chou, SY; Fitzgerald, JP; Franco, I; Gulmi, FA; Kim, H; Mooppan, UM; Saini, R | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN | 1 |
| Chaiyakunapruk, N; Cheewasithirungrueng, N; Dilokthornsakul, P; Jeanpeerapong, N; Nimpitakpong, P; Srisupha-olarn, W; Thanarungroj, A | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| French, J; Gruben, D; Tan, H; Thomas, N | 1 |
| Ahmadi, A; Hajikhani, R; Pakzad, S; Solati, J | 1 |
| Akilli, H; Alihanoglu, Y; Altunkeser, BB; Aribas, A; Ayhan, S; Can, I; Demir, K; Koc, F; Vatankulu, MA | 1 |
| Takagi, H; Umemoto, T | 1 |
| Asakawa, M; Chiba, K; Kawasumi, M; Kobayashi, T; Miyamoto, T; Mori, T; Morioka, H; Toyama, Y; Yoshida, H; Yoshimura, A | 1 |
| Mardiak, J; Mego, M; Obertova, J; Reckova, M; Svetlovska, D; Sycova-Mila, Z | 1 |
| Buonanno, M; Gupta, P; Harness, JA; Krishnaswami, S; Langley, RG; Menter, A; Papp, KA; Strober, B; Tan, H; Wolk, R | 1 |
| Bahrami, A; Farid Hosseini, R; Jabbari, F; Pezeshkpoor, F; Rafatpanah, H; Sadri, H; Shakerian, B; Yousefzadeh, H; Zamani, MA; Zandkarimi, MR | 1 |
| Kalonia, H; Kumar, A; Kumar, P; Mishra, J; Vashist, A | 1 |
| Bissonnette, R; Bolduc, C; Khan, S; Lamba, M; Lan, S; Papp, K; Ports, WC | 1 |
| Abman, SH; Le Cras, TD; Markham, NE; Tuder, RM; Voelkel, NF | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Gersh, BJ; Raco, DL; Rihal, CS; Yusuf, S | 1 |
| Fukao, K; Kobayashi, S; Nagai, M; Seino, K; Shikata, K; Taniguchi, M; Yamauchi, T | 1 |
| Kato, H; Narita, M; Oe, K; Shibasaki, M; Suzuki, T; Yajima, Y; Yamazaki, M | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM | 1 |
| Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Kiberd, BA | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Chou, SY; Gulmi, FA; Kim, H; Michli, E; Mooppan, UM | 1 |
| Dudek, AZ; Keshtgarpour, M | 1 |
| Gu, M; Liu, M; Wu, Y; Yin, C; Zhang, W; Zhu, P | 1 |
| Miranda, A; Nordstrom, E; Sengupta, JN; Smith, C | 1 |
| Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
| Bertorelli, R; Burnett, DA; Domalski, M; Fredduzzi, S; Greenlee, WJ; Li, C; Lozza, G; Reggiani, A; Veltri, A; Wu, WL | 1 |
| Campese, VM; Park, J | 1 |
| Paraskevas, KI | 1 |
| Bradesi, S; Larauche, M; Mayer, EA; McLean, P; McRoberts, JA; Million, M; Taché, Y | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
| Kaufman, J; Renz, RH; Smith, S; Sohler, A | 1 |
| Balderrama, DS; Eichinger, MR; Herrera, GM; Resta, JM; Resta, TC; Richardson, LA; Walker, BR | 1 |
| Blauw, GJ; de Man, FH; Jukema, JW; Smelt, AH; van der Laarse, A; Weverling-Rijnsburger, AW | 1 |
| Anliker, MD; Wüthrich, B | 1 |
| Heidrich, G; Houde, RW; Kaiko, RF; Rogers, A; Wallenstein, SL | 1 |
| Cruz, R; Vogel, WH | 1 |
| Aylward, M; Holly, F; Maddock, J; Parker, RJ; Thomas, SR | 1 |
| Dolan, BJ; Flach, AJ; Irvine, AR | 1 |
| Amadio, P; Cummings, DM | 1 |
| Pavelka, K; Susta, A | 1 |
| Andreeva, PG; Givental', NI; Kushnareva, TO | 1 |
| Ivanova, TI; Kekalo, LA; Neĭko, EM; Olgina, FP | 1 |
14 review(s) available for pyrroles and Chronic Disease
| Article | Year |
|---|---|
Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy.
Topics: Adult; Chronic Disease; Eosinophilic Esophagitis; Female; Humans; Japan; Male; Middle Aged; Prevalence; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Neck vein obstruction: Diagnosis and the role of chronic persistent
Topics: Chlamydophila Infections; Chlamydophila pneumoniae; Chronic Disease; Humans; Neck; Pyrimidines; Pyrroles; Vascular Diseases | 2019 |
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Topics: Chronic Disease; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies.
Topics: Atorvastatin; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MEDLINE; Prospective Studies; Pyrroles | 2014 |
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Chronic Disease; Female; Humans; Lipids; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylarthritis; Treatment Outcome | 2015 |
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Topics: Chronic Disease; Clinical Trials as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2016 |
[Etiology, diagnostics and therapy of hyponatremias].
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain Diseases; Central Nervous System; Chronic Disease; Demeclocycline; Demyelinating Diseases; Diagnosis, Differential; Diuretics; Extracellular Fluid; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lithium Compounds; Morpholines; Osmolar Concentration; Osmosis; Pyrroles; Severity of Illness Index; Sodium; Spiro Compounds; Time Factors; Tolvaptan; Vasopressins | 2008 |
[Chronic transplant nephropathy].
Topics: Animals; Atorvastatin; Atrophy; Biopsy; Chronic Disease; Complement C4b; Heptanoic Acids; Humans; Kidney Transplantation; Kidney Tubules; Nephritis, Interstitial; Peptide Fragments; Postoperative Complications; Pyridoxamine; Pyrroles; Rats; Risk Factors; Terminology as Topic; Transplants | 2008 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Topics: Atorvastatin; Chronic Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Chronic Disease; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
28 trial(s) available for pyrroles and Chronic Disease
| Article | Year |
|---|---|
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Topics: Adolescent; Adult; Aged; Basophils; Blood Cell Count; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Hematocrit; Hemoglobins; Humans; Killer Cells, Natural; Leukocytes; Male; Middle Aged; Monocytes; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Young Adult | 2013 |
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Retreatment; Treatment Outcome; Young Adult | 2015 |
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2015 |
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Topics: Chronic Disease; Dermatologic Agents; Etanercept; Humans; Patient Satisfaction; Piperidines; Placebos; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Topics: Chronic Disease; Dermatologic Agents; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2017 |
Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Agents; Asthma; Atorvastatin; Biomarkers; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sputum; Vital Capacity | 2008 |
Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Electrocardiography; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long QT Syndrome; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2010 |
The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.
Topics: Adult; Aged; Analgesia; Anesthetics, Local; Chronic Disease; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Hyperalgesia; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Neuralgia; Pain Measurement; Peripheral Nerve Injuries; Peripheral Nerves; Peripheral Nervous System Diseases; Pyrroles; Receptors, AMPA; Receptors, Kainic Acid; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Young Adult | 2009 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets | 2010 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy.
Topics: Analysis of Variance; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Chronic Disease; Electric Countershock; Female; Fibrinogen; Health Status Indicators; Heptanoic Acids; Humans; Leukocyte Count; Male; Middle Aged; Pyrroles; Secondary Prevention; Time Factors; Warfarin | 2011 |
Sunitinib in patients with cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Female; Humans; Indoles; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Slovakia; Sunitinib; Treatment Outcome | 2012 |
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Topics: Administration, Oral; Adult; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Efficacy of atorvastatin and antihistamines in comparison with antihistamines plus placebo in the treatment of chronic idiopathic urticaria: a controlled clinical trial.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Chronic Disease; Cytokines; Drug Therapy, Combination; Female; Heptanoic Acids; Histamine Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Iran; Male; Middle Aged; Pyrroles; Severity of Illness Index; Single-Blind Method; Time Factors; Treatment Outcome; Urticaria; Young Adult | 2012 |
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Topics: Administration, Cutaneous; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2013 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Coenzymes; Cross-Over Studies; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Vascular Resistance; Vasodilation | 2005 |
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides | 2005 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
Topics: Acetylcholine; Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Chronic Disease; Endothelium, Vascular; Free Radical Scavengers; Heptanoic Acids; Humans; Hypertriglyceridemia; Injections, Intravenous; Male; Middle Aged; Nitroprusside; Pyrroles; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2000 |
Evaluation of tolmetin in the treatment of arthritis: open and controlled double-blind studies.
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indomethacin; Male; Middle Aged; Pyrroles; Tolmetin | 1976 |
Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aphakia, Postcataract; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Ketorolac Tromethamine; Lenses, Intraocular; Macular Edema; Ophthalmic Solutions; Pyrroles; Random Allocation; Time Factors; Tolmetin; Tromethamine; Visual Acuity | 1987 |
The effect of tolmetin on the chronic pain and decreased functional capacity associated with degenerative joint disease.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain; Pyrroles; Random Allocation; Tolmetin | 1985 |
[Tolmetin, a new non-steroid antirheumatic agent].
Topics: Anti-Inflammatory Agents; Arthritis; Benzoates; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Humans; Placebos; Pyrroles | 1974 |
55 other study(ies) available for pyrroles and Chronic Disease
| Article | Year |
|---|---|
Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
Topics: Animals; Cells, Cultured; Chronic Disease; Disease Models, Animal; Endothelial Cells; Epithelial-Mesenchymal Transition; Glucosides; Humans; Hypoxia; Indoles; Injections, Subcutaneous; Male; Monoterpenes; Oxygen; Pulmonary Arterial Hypertension; Pyrroles; Rats; Rats, Sprague-Dawley | 2020 |
Cytochrome P450 Epoxygenase-Dependent Activation of TRPV4 Channel Participates in Enhanced Serotonin-Induced Pulmonary Vasoconstriction in Chronic Hypoxic Pulmonary Hypertension.
Topics: Amides; Animals; Chronic Disease; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Eicosanoids; Hypertension, Pulmonary; Hypoxia; Ion Channel Gating; Male; Mice, Inbred C57BL; Morpholines; Pulmonary Artery; Pyrroles; Serotonin; TRPV Cation Channels; Vasoconstriction | 2020 |
Real-world efficacy, tolerability, and safety of ubrogepant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arizona; Calcitonin Gene-Related Peptide Receptor Antagonists; Chronic Disease; Cohort Studies; Female; Headache; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyridines; Pyrroles; Surveys and Questionnaires; Tertiary Care Centers; Treatment Outcome; Young Adult | 2021 |
Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model.
Topics: Allografts; Animals; Chronic Disease; Disease Models, Animal; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Graft Rejection; Humans; Interleukin-6; Janus Kinases; Kidney Transplantation; Piperidines; Pyrroles; Rats; Rats, Inbred Lew; Tacrolimus | 2018 |
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Topics: Arthritis, Rheumatoid; Chronic Disease; Female; Herpes Zoster; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin; Skin Ulcer | 2018 |
Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Topics: Animals; Chronic Disease; Complement C4b; Disease Models, Animal; Disease Progression; Graft Rejection; Graft Survival; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppressive Agents; Janus Kinase 3; Kidney; Kidney Transplantation; Male; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; Signal Transduction; Treatment Outcome | 2018 |
Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice.
Topics: Adoptive Transfer; Adult; Animals; Antibodies; Blood Pressure; Bone Marrow; Cell Proliferation; Chimera; Chronic Disease; Disease Models, Animal; Female; Gene Deletion; Humans; Hypertension, Pulmonary; Hypoxia; Immunity; Indoles; Lung; Lymphocyte Activation; Male; Mice; Ovalbumin; Pulmonary Artery; Pyrroles; Receptors, Immunologic; Receptors, Prostaglandin; STAT6 Transcription Factor; Th2 Cells; Up-Regulation | 2018 |
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Young Adult | 2019 |
SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.
Topics: Angiogenesis Inhibitors; Animals; Chronic Disease; Heart Ventricles; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles | 2019 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Chronic Disease; DNA; Fibroblasts; Flow Cytometry; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2013 |
TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension.
Topics: Animals; Calcium Signaling; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Hypoxia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Pulmonary Artery; Pyrroles; Serotonin; Sulfonamides; Time Factors; TRPV Cation Channels; Vasoconstriction; Vasoconstrictor Agents | 2013 |
Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice.
Topics: Animals; Antibodies, Monoclonal; Bone Morphogenetic Proteins; Chronic Disease; Familial Primary Pulmonary Hypertension; Heart Ventricles; HEK293 Cells; Hemodynamics; Humans; Hypertension, Pulmonary; Hypoxia; Indoles; Intercellular Signaling Peptides and Proteins; Lung; Mice; Pyrroles; Signal Transduction | 2013 |
Changes in large pulmonary arterial viscoelasticity in chronic pulmonary hypertension.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Chronic Disease; Collagen; Elastic Modulus; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Mice; Mice, Inbred C57BL; Myocytes, Smooth Muscle; Proteoglycans; Pyrroles; Stress, Mechanical; Vascular Stiffness; Ventricular Dysfunction, Right; Viscosity | 2013 |
In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.
Topics: Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Janus Kinase 3; Killer Cells, Natural; Macaca mulatta; Piperidines; Pyrimidines; Pyrroles; Simian Acquired Immunodeficiency Syndrome; Viral Load | 2014 |
[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Drug Approval; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Switzerland | 2014 |
Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Chronic Disease; Cohort Studies; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Diseases; Male; Middle Aged; Pyrroles; Risk; Severity of Illness Index; Taiwan; Time Factors | 2015 |
Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Astrocytes; Benzamides; Blood-Brain Barrier; Brain Diseases; Chronic Disease; Demyelinating Diseases; Hyponatremia; Male; Microglia; Pyrroles; Rats; Rats, Wistar; Saline Solution, Hypertonic; Urea | 2015 |
The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
Topics: Adrenergic alpha-Agonists; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chronic Disease; Colorectal Neoplasms; Disease Models, Animal; Female; Humans; Indoles; Interleukin-8; Mice; Mice, Inbred BALB C; Norepinephrine; Pyrroles; Receptors, Adrenergic, beta; Signal Transduction; Stress, Psychological; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model.
Topics: Administration, Oral; Allografts; Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Graft Rejection; Indoles; Kidney; Kidney Transplantation; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrroles; Rats, Wistar; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factors | 2016 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Middle Aged; Patient Safety; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2016 |
Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.
Topics: Animals; Cardiomegaly; Cell Proliferation; Chronic Disease; Heart Function Tests; Hemodynamics; Hyperplasia; Hypertension, Pulmonary; Hypoxia; Indoles; Ki-67 Antigen; Lung; Male; Microspheres; Oxygen Consumption; P-Selectin; Partial Pressure; Physical Conditioning, Animal; Plasminogen Activator Inhibitor 1; Polystyrenes; Pulmonary Embolism; Pyrroles; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Vascular Endothelial Growth Factor A; Ventricular Dysfunction | 2017 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Heart Failure; Heptanoic Acids; Humans; Pyrroles; Signal Transduction; Th1 Cells; Th2 Cells | 2009 |
Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
Topics: Animals; Atorvastatin; Chronic Disease; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2009 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, University; Humans; Male; Middle Aged; Pharmaceutical Preparations; Phenylcarbamates; Pyrroles; Retrospective Studies; Rivastigmine; Rosiglitazone; Tetrazoles; Thailand; Thiazolidinediones; Ticlopidine; Valine; Valsartan | 2012 |
A case study of model-based Bayesian dose response estimation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Nonlinear Dynamics; Piperidines; Pyrimidines; Pyrroles | 2011 |
Synthesis and analgesic effects of new pyrrole derivatives of phencyclidine in mice.
Topics: Analgesics; Animals; Chronic Disease; Dimethyl Sulfoxide; Formaldehyde; Hot Temperature; Indicators and Reagents; Methylation; Mice; Pain Measurement; Phencyclidine; Pyrroles; Structure-Activity Relationship | 2011 |
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Chronic Disease; Enzyme Inhibitors; Fibroblasts; Gene Expression; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Joints; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Osteoclasts; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2011 |
Potential role of licofelone, minocycline and their combination against chronic fatigue stress induced behavioral, biochemical and mitochondrial alterations in mice.
Topics: Animals; Chronic Disease; Drug Therapy, Combination; Fatigue; Glutathione; Lipid Peroxidation; Male; Maze Learning; Mice; Minocycline; Mitochondria; Motor Activity; Pyrroles; Stress, Psychological | 2012 |
Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.
Topics: Angiography; Animals; Animals, Newborn; Birth Weight; Chronic Disease; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Pulmonary Alveoli; Pulmonary Artery; Pulmonary Circulation; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Stress, Physiological | 2002 |
Prevention of acute and chronic allograft rejection by a novel retinoic acid receptor-alpha-selective agonist.
Topics: Acute Disease; Animals; Arteriosclerosis Obliterans; Chronic Disease; Cyclin-Dependent Kinase Inhibitor Proteins; Cytokines; Furans; Graft Enhancement, Immunologic; Graft Rejection; Heart Transplantation; Lymphocyte Activation; Mice; Mice, Inbred Strains; Microtubule-Associated Proteins; Myocytes, Smooth Muscle; Pyrroles; Rats; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Spleen; T-Lymphocytes, Cytotoxic | 2004 |
Implication of spinal protein kinase C in the suppression of morphine-induced rewarding effect under a neuropathic pain-like state in mice.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Disease Models, Animal; Enzyme Inhibitors; Indoles; Ligation; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Dependence; Neuralgia; Protein Kinase C; Pyrroles; Reward; Sciatic Neuropathy; Spinal Cord; Up-Regulation | 2004 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Chronic Disease; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerulonephritis; Heptanoic Acids; Humans; Insulin; Insulin, Long-Acting; Insulin, Regular, Human; Lipoproteins; Male; Middle Aged; Proteinuria; Pyrroles; Retrospective Studies; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome | 2005 |
Statins and autonomic function in chronic heart failure.
Topics: Atorvastatin; Autonomic Nervous System; Chronic Disease; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Atorvastatin preserves renal function in chronic complete unilateral ureteral obstruction.
Topics: Animals; Atorvastatin; Chronic Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2007 |
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.
Topics: Angiogenesis Inhibitors; Chronic Disease; Humans; Indoles; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chemokines; Chronic Disease; Cyclosporine; Cytokines; Drug Therapy, Combination; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Graft Rejection; Heptanoic Acids; Immunosuppressive Agents; Kidney Transplantation; Male; Monocytes; Proteinuria; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous | 2007 |
Neonatal gastric suctioning results in chronic visceral and somatic hyperalgesia: role of corticotropin releasing factor.
Topics: Abdominal Pain; Animals; Animals, Newborn; Catheterization; Chronic Disease; Corticotropin-Releasing Hormone; Gastric Mucosa; Hot Temperature; Hyperalgesia; Intubation, Gastrointestinal; Male; Manometry; Nociceptors; Pyrimidines; Pyrroles; Rats; Rats, Long-Evans; Receptors, Corticotropin-Releasing Hormone; Suction | 2007 |
Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain.
Topics: Analgesics; Animals; Area Under Curve; Chronic Disease; Heterocyclic Compounds, 4 or More Rings; Humans; Indazoles; Morpholines; Pain; Peripheral Nervous System Diseases; Pyridines; Pyrroles; Rats; Receptors, Metabotropic Glutamate; Structure-Activity Relationship | 2007 |
HMG-CoA reductase inhibitors and renal function.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles | 2007 |
Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats.
Topics: Animals; Blood-Brain Barrier; Chronic Disease; Colon; Corticotropin-Releasing Hormone; Disease Models, Animal; Hyperalgesia; Infusion Pumps, Implantable; Injections, Subcutaneous; Male; Mechanotransduction, Cellular; Peptide Fragments; Pressure; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone; Rectum; Stress, Psychological | 2008 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
Significance of hydroxyskatole and mauve factor excretion in schizophrenia.
Topics: Adult; Alcoholism; Chromatography, Thin Layer; Chronic Disease; Epilepsy; Furans; Humans; Indoles; Male; Middle Aged; Pyrroles; Schizophrenia | 1967 |
Glibenclamide does not reverse attenuated vasoreactivity to acute or chronic hypoxia.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Benzopyrans; Blood Gas Analysis; Blood Pressure; Chronic Disease; Cromakalim; Glyburide; Heart Rate; Hemodynamics; Hypoglycemic Agents; Hypoxia; Male; Phenylephrine; Potassium Channels; Pyrroles; Rats; Rats, Sprague-Dawley; Vascular Resistance; Vasoconstrictor Agents | 1995 |
Chronic urticaria to atorvastatin.
Topics: Atorvastatin; Chronic Disease; Drug Hypersensitivity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Urticaria | 2002 |
Clinical analgesic assay of oral zomepirac and intramuscular morphine.
Topics: Administration, Oral; Affect; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Morphine; Pain; Pain, Postoperative; Pyrroles; Research Design; Tolmetin | 1979 |
Pyroluria: a poor marker in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Pyrroles; Schizophrenia; Vitamin B 6 Deficiency; Zinc | 1978 |
[Use of polysaccharide prodigiozan in the complex therapy of chronic and residual brucellosis].
Topics: Adult; Anti-Bacterial Agents; Ascorbic Acid; Brucellosis; Chronic Disease; Drug Hypersensitivity; Female; Humans; Immunotherapy; Male; Middle Aged; Muramidase; Oleandomycin; Phagocytosis; Physical Therapy Modalities; Pigments, Biological; Prodigiosin; Pyrroles; Serratia marcescens; Stimulation, Chemical; Tetracycline; Vitamins | 1971 |
[Indices of outer respiration in complex therapy of chronic pneumonia using prodigiosin].
Topics: Adult; Aged; Anti-Bacterial Agents; Chronic Disease; Humans; Middle Aged; Pigments, Biological; Pneumonia; Prodigiosin; Pyrroles; Respiration | 1972 |